SCHEMBL14686209

SCHEMBL14686209

N=C(N)NCc1ccc(CN)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 7/20 0.59
LOXL2 Q9Y4K0 3/20 0.54
F10 P00742 2/20 0.54
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
ABAT P80404 1/20 0.44
PRSS1 P07477 2/20 0.44
TPSD1 Q9BZJ3 1/20 0.44
TPSG1 Q9NRR2 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
F2 P00734 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
ST14 Q9Y5Y6 2/20 0.41
PLG P00747 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3046366 0.98 TPSAB1 (0.57) TPSAB1LOXL2F10CYP2C9CYP2C19
SCHEMBL3672272 0.91 CYP2C9 (0.48) TPSAB1LOXL2F10CYP2C9CYP2C19
SCHEMBL31540904 0.84 LOXL2 (0.55) TPSAB1LOXL2F10CYP2C9CYP2C19
SCHEMBL4103299 0.83 ABAT (0.44) CYP2C9CYP2C19ABAT
SCHEMBL6881703 0.83 CYP2C9 (0.42) TPSAB1CYP2C9CYP2C19PRSS1F2
SCHEMBL6881708 0.83 EPHX2 (0.45) TPSAB1LOXL2CYP2C9CYP2C19TSHR
SCHEMBL14764132 0.82 ST14 (0.42) TPSAB1LOXL2F10CYP2C9CYP2C19
SCHEMBL16216331 0.82 ST14 (0.42) TPSAB1LOXL2F10CYP2C9CYP2C19
SCHEMBL11981491 0.81 IDO1 (0.52) CYP2C9CYP2C19
SCHEMBL18401332 0.81 CYP2C9 (0.41) TPSAB1CYP2C9CYP2C19PRSS1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP claimed
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP claimed
CN-119998365-A Anion exchange separation articles, methods of manufacture, and methods of use 舒万诺知识产权公司 2025-05-13 CN disclosed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 WO disclosed
US-8846705-B2 Diaminopyrimidines as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2014-09-30 US disclosed
EP-1699455-B1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 TPSAB1 4884/4885LOXL2 3557/4885F10 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.